drug · antibody
KESIMPTA
Marketedupdated 6mo agoby $NVS NOVARTIS AG🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Antibody drug with a maximum clinical stage of Approval (across all indications), with 5 approved and 17 investigational indications.
targets
B-lymphocyte antigen CD20
all catalysts(13)
approval · 13
Oct 26, 2009
approval
$NVS155.21-2.46%
KESIMPTA (OFATUMUMAB) — FDA approval
KESIMPTA
→
Sep 23, 2010
approval
$NVS155.21-2.46%
KESIMPTA (OFATUMUMAB) — FDA approval
KESIMPTA
→
Sep 20, 2011
approval
$NVS155.21-2.46%
KESIMPTA (OFATUMUMAB) — FDA approval
KESIMPTA
→
Sep 24, 2013
approval
$NVS155.21-2.46%
KESIMPTA (OFATUMUMAB) — FDA approval
KESIMPTA
→
Apr 17, 2014
approval
$NVS155.21-2.46%
KESIMPTA (OFATUMUMAB) — FDA approval
KESIMPTA
→
Jan 19, 2016
approval
$NVS155.21-2.46%
KESIMPTA (OFATUMUMAB) — FDA approval
KESIMPTA
→
Aug 30, 2016
approval
$NVS155.21-2.46%
KESIMPTA (OFATUMUMAB) — FDA approval
KESIMPTA
→
Aug 20, 2020
approval
$NVS155.21-2.46%
KESIMPTA (OFATUMUMAB) — FDA approval
KESIMPTA
→
Sep 2, 2022
approval
$NVS155.21-2.46%
KESIMPTA (OFATUMUMAB) — FDA approval
KESIMPTA
→
Jan 19, 2024
approval
$NVS155.21-2.46%
KESIMPTA (OFATUMUMAB) — FDA approval
KESIMPTA
→
Apr 12, 2024
approval
$NVS155.21-2.46%
KESIMPTA (OFATUMUMAB) — FDA approval
KESIMPTA
→
Aug 18, 2025
approval
$NVS155.21-2.46%
KESIMPTA (OFATUMUMAB) — FDA approval
KESIMPTA
→
Apr 1, 2026
approval
$NVS155.21-2.46%
KESIMPTA (OFATUMUMAB) — FDA approval
KESIMPTA
→
Trials studying KESIMPTA
- —A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
- —Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab
- —A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
- —Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France
- phase3Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
- —Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational Study
- —ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients
- phase3An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to Ofatumumab
News(7)
- Novartis CEO argues shareholders ‘happy overall’ with strategy, calls for COINS Act adjustmentDespite a bumpy few months for Novartis that saw a couple of high-profile clinical setbacks, CEO Vas Narasimhan has told Fierce he believes most shareholders remain onside with the company’s strategy.fiercebiotech · 8h ago
- Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting gameLilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.biopharma_dive · 20d ago
- Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buyNovartis remains "very happy" with its $12 billion acquisition of Avidity Biosciences, despite a Phase 3 disappointment for the antibody-oligonucleotide conjugate del-desiran.biospace · 22d ago
- Novartis drops $125M for Sironax’s tech to cross blood-brain barrierNovartis stands alongside Big Pharma peers that have similarly invested in technologies to penetrate the blood-brain barrier, including GSK, Roche and Eli Lilly.biospace · 2mo ago
- Novartis’ board faces investor scrutiny after M&A misfires and R&D flopsBack-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit of drugs to drive growth through the 2030s.biospace · 2mo ago
- Novartis climbs on upbeat drug sales as key readouts loomA return to quarterly sales growth boosted shares higher on Tuesday, though a handful of coming study results will have a bigger impact on the company’s long-term outlook.biopharma_dive · 4mo ago
- Novartis stays 'geography-agnostic' in dealmaking amid flurry of China dealsNovartis will continue to be on the lookout for bolt-on deals below $2 billion, CEO Vas Narasimhan said Tuesday on the pharma's second quarter earnings call—though major pickups aren’t completely o…biospace · 4mo ago
Data sources
last refreshed 2h ago
Found something off?
comments(0)
5-min edit window · permanent after that